PATH chooses Mymetics for work on transmission-blocking malaria vaccine

With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative (MVI) has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate. The biotech will work alongside the Laboratory of Malaria Immunology and Vaccinology, part of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), it said. Release | More